Study of TB511 for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary clinical trials.
This trial tests an investigational drug called TB511, either alone or with an immunotherapy, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if TB511 can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have an advanced solid tumor that has not responded to or stopped responding to standard treatments, including immune checkpoint inhibitors (like anti-PD-1 drugs) for some groups.
- You are able to perform daily activities without significant help (ECOG score 0 or 1).
- If you are of childbearing potential, you must agree to use effective birth control for 6 months after the last dose of study drug.
- You have not had chemotherapy, radiation, or other cancer treatment in the 4 weeks before starting the trial.
- You do not have untreated or symptomatic brain metastases, active autoimmune disease, or significant heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to understand how the body handles the drug and what side effects may occur. It may be an option if your tumor has a specific marker called ROR1.
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests an experimental tablet called TQB3217 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and helps shrink or control the tumor.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.